ODI Pharma AB (publ) reported earnings results for the second quarter and six months ended December 31, 2021. For the second quarter, the company reported sales was SEK 0.45862 million. Revenue was SEK 0.516768 million compared to SEK 0.015278 million a year ago. Net loss was SEK 1.4 million compared to SEK 0.772093 million a year ago. Basic loss per share from continuing operations was SEK 0.09 compared to SEK 0.05 a year ago.
For the six months, sales was SEK 0.45862 million. Revenue was SEK 0.517085 million compared to SEK 0.015697 million a year ago. Net loss was SEK 2.58 million compared to SEK 2.05 million a year ago. Basic loss per share from continuing operations was SEK 0.17 compared to SEK 0.13 a year ago.